TXO:NYSETXO Partners, L.P. Analysis
Data as of 2026-06-14 - not real-time
$13.17
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TXO is trading just below its short‑term moving average, with price hugging a clear support level while facing a modest resistance ceiling. The 14‑day RSI sits near the midpoint, suggesting neither overbought nor oversold conditions, and the MACD histogram is negative, indicating short‑term bearish momentum despite an overall bullish trend direction. Volume has been picking up and volatility remains elevated, aligning with the market’s “extreme greed” sentiment.
Fundamentally, the company shows a stark contrast between a strong dividend yield and deteriorating profitability, highlighted by negative trailing earnings and a modest forward earnings outlook. The forward P/E is well below the industry average, and the discounted cash‑flow model places fair value above the current price, implying upside potential. However, high leverage, a sizable debt load, and negative free cash flow raise concerns about the sustainability of the dividend and long‑term cash generation.
Fundamentally, the company shows a stark contrast between a strong dividend yield and deteriorating profitability, highlighted by negative trailing earnings and a modest forward earnings outlook. The forward P/E is well below the industry average, and the discounted cash‑flow model places fair value above the current price, implying upside potential. However, high leverage, a sizable debt load, and negative free cash flow raise concerns about the sustainability of the dividend and long‑term cash generation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near immediate support
- negative MACD histogram
- elevated volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value above market price
- forward P/E advantage vs peers
- high dividend yield attracting income seekers
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- potential upside to analyst target range
- value‑oriented pricing relative to industry
- asset base in prolific North American basins
Key Metrics & Analysis
Financial Health
Revenue Growth-66.50%
Profit Margin-28.52%
P/E Ratio13.6
ROE-16.49%
ROA-5.55%
Debt/Equity45.84
P/B Ratio1.0
Op. Cash Flow$121.0M
Free Cash Flow$-117653000
Industry P/E21.5
Technical Analysis
TrendBullish
RSI50.6
Support$12.39
Resistance$14.14
MA 20$13.33
MA 50$12.73
MA 200$12.64
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$15.42
Target Price$21.00
Upside/Downside59.45%
GradeUndervalued
TypeValue
Dividend Yield11.09%
Risk Assessment
Beta-0.08
Volatility32.83%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.